Zacks Investment ResearchThu, 07 May 2026 15:01:03 GMTIntellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?NTLA+2.77%
Zacks Investment ResearchTue, 28 Apr 2026 18:06:11 GMTNTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLANTLA+2.77%
Seeking AlphaMon, 27 Apr 2026 19:11:47 GMTIntellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema TranscriptNTLA+2.77%
Investors Business DailyMon, 27 Apr 2026 15:04:29 GMTThis Biotech Just Lodged A First In Gene Editing; Why Analysts Are SplitNTLA+2.77%
BenzingaMon, 27 Apr 2026 14:07:20 GMTIntellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To TestNTLA+2.77%
CNBCMon, 27 Apr 2026 11:01:01 GMTIntellia Therapeutics says its Crispr-based treatment succeeds in pivotal trialNTLA+2.77%
Zacks Investment ResearchThu, 16 Apr 2026 14:36:07 GMTNTLA Stock Rises 20% in 3 Months: Here's What You Should KnowNTLA+2.77%
The Motley FoolSun, 08 Mar 2026 21:28:00 GMTThis Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?NTLA+2.77%
BenzingaMon, 02 Mar 2026 15:05:50 GMTIntellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal TrialNTLA+2.77%
Zacks Investment ResearchFri, 27 Feb 2026 17:15:36 GMTIntellia Rises on Q4 Earnings & Revenue Beat, Focuses on PipelineNTLA+2.77%
Seeking AlphaFri, 27 Feb 2026 02:47:52 GMTIntellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call TranscriptNTLA+2.77%
Zacks Investment ResearchThu, 26 Feb 2026 18:16:09 GMTIntellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue EstimatesNTLA+2.77%
